Oxidant-increased endothelial permeability: prevention with phosphodiesterase inhibition vs. cAMP production.
The present objective was to determine whether hydrogen peroxide (H(2)O(2)) increases transvascular albumin clearance and lung weight in an isolated rat lung and whether posttreatment with cAMP-enhancing agents can prevent these increases. Transvascular albumin clearance was assessed by (125)I-labeled albumin clearance ((125)I-albumin flux/perfusate concentration of (125)I-albumin) at a given fluid filtration. Nonlinear regression analysis of transvascular albumin clearance vs. fluid filtration yielded values for the permeability-surface area product (PS) and the reflection coefficient (sigma). H(2)O(2) decreased sigma from a control value of 0.93 to 0.38, did not change PS, and increased lung weight. Posttreatment with isoproterenol, a beta(2)-adrenergic-receptor agonist, reduced the H(2)O(2)-induced decrease in sigma to 0.65 and augmented the increase in lung weight. Posttreatment with CP-80633, a phosphodiesterase 4 inhibitor, further reduced the H(2)O(2)-induced decrease in sigma to 0.79 and blocked the rise in lung weight. In the presence of isoproterenol or CP-80633, H(2)O(2) increased PS. Therefore, H(2)O(2) increased the convective and diffusive clearances of albumin across an intact pulmonary vasculature. Furthermore, inhibition of cAMP metabolism more effectively attenuated the H(2)O(2)-induced increases in convective albumin clearance and lung weight as compared with stimulation of cAMP production.
Waypa
G B
GB
Vascular Biology Research Group and Department of Physiology and Cell Biology, Albany Medical College, Albany, New York 12208-3479, USA.
Morton
C A
CA
Vincent
P A
PA
Mahoney
J R
JR
Johnston
W K
WK
Minnear
F L
FL
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects*; D002614:Chelating Agents / Q000494:pharmacology; D000242:Cyclic AMP / Q000096:biosynthesis*; D003676:Deferoxamine / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000502:physiology*; D006861:Hydrogen Peroxide / Q000633:toxicity*; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D008168:Lung / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010477:Perfusion; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011744:Pyrimidinones / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012710:Serum Albumin, Bovine / Q000378:metabolism
D000318:Adrenergic beta-Agonists; C101589:CP 80633; D002614:Chelating Agents; D010726:Phosphodiesterase Inhibitors; D011744:Pyrimidinones; D012710:Serum Albumin, Bovine; D006861:Hydrogen Peroxide; D000242:Cyclic AMP; D003676:Deferoxamine; D007545:Isoproterenol